Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

2.600 +0.120 (+4.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,622
Open 2.500
Bid (Size) 2.510 (1,000)
Ask (Size) 2.630 (100)
Prev. Close 2.480
Today's Range 2.500 - 2.636
52wk Range 2.200 - 6.520
Shares Outstanding 3,192,040
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-25.1%
-25.1%
1 Month
-0.4%
-0.4%
3 Month
-15.9%
-15.9%
6 Month
-21.0%
-21.0%
1 Year
-41.2%
-41.2%

More News

Read More
News headline image
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2025 ↗
Via Benzinga
News headline image
Cellectar (CLRB) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar (CLRB) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Expands Global Intellectual Property Estate
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Outlook For Cellectar Biosciences ↗
Via Benzinga
News headline image
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally ↗
Via Stocktwits
Topics Supply Chain

Frequently Asked Questions

Is Cellectar Biosciences, Inc. - Common Stock publicly traded?
Yes, Cellectar Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Cellectar Biosciences, Inc. - Common Stock trade on?
Cellectar Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectar Biosciences, Inc. - Common Stock?
The ticker symbol for Cellectar Biosciences, Inc. - Common Stock is CLRB on the Nasdaq Stock Market
What is the current price of Cellectar Biosciences, Inc. - Common Stock?
The current price of Cellectar Biosciences, Inc. - Common Stock is 2.600
When was Cellectar Biosciences, Inc. - Common Stock last traded?
The last trade of Cellectar Biosciences, Inc. - Common Stock was at 08/14/26 04:00 PM ET
What is the market capitalization of Cellectar Biosciences, Inc. - Common Stock?
The market capitalization of Cellectar Biosciences, Inc. - Common Stock is 8.30M
How many shares of Cellectar Biosciences, Inc. - Common Stock are outstanding?
Cellectar Biosciences, Inc. - Common Stock has 8M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.